Resting heart rate and outcomes in patients with cardiovascular disease: Where do we currently stand?

Cardiovascular Therapeutics

Volumn 31, Issue 4, 2013, Pages 215-223

  Menown, Ian B A ^a   Davies, Simon ^b   Gupta, Sandeep ^c   Kalra, Paul R ^d   Lang, Chim C ^e   Morley, Chris ^f   Padmanabhan, Sandosh ^g  

^a Craigavon Cardiac Centre   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f BRADFORD ROYAL INFIRMARY   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Angina; Beta blockers; Calcium channel blockers; Cardiovascular risk; Coronary artery disease; Heart failure; If Channel blockers

Indexed keywords

AMLODIPINE; ATENOLOL; BENDROFLUMETHIAZIDE; BISOPROLOL; C REACTIVE PROTEIN; CAPADENOSON; DIGOXIN; DILTIAZEM; IVABRADINE; METOPROLOL; PERINDOPRIL; PLACEBO; UNCLASSIFIED DRUG; VERAPAMIL; YM 758;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ANEMIA; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; AORTA PRESSURE; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ELECTROCARDIOGRAPHY MONITORING; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPOPHILICITY; LONG TERM SURVIVAL; LUNG CONGESTION; META ANALYSIS (TOPIC); NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBESITY; OUTCOME ASSESSMENT; PARASYMPATHETIC TONE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING HEART RATE; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; UNSTABLE ANGINA PECTORIS;

ANGINA; BETA-BLOCKERS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; HEART FAILURE; IF CHANNEL BLOCKERS;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HEART RATE; HUMANS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84880692000     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2012.00321.x     Document Type: Article

References (53)

1. Cooney MT, Vartiainen E, Laatikainen T, Juolevi A, Dudina A, Graham IM. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 2010;159:612-619. e3.
2. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-974.
3. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: Findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008;29:1327-1334.
4. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821.
5. Menown IBA. Resting heart rate as a cardiovascular risk factor? MIMS Cardiovascular 2008;3:18-21.
6. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J 1993;125:1148-1154.
7. Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: Role of age, gender, and blood pressure. Hypertension 1999;33:44-52.
8. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: The NHANES I Epidemiologic Follow-up Study. Am Heart J 1991;121:172-177.
9. Palatini P, Thijs L, Staessen JA, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002;162:2313-2321.
10. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010;31:2271-2279.
11. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005;366:895-906.
12. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol 2012;109:685-692.
13. Paul L, Hastie CE, Li WS, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension 2010;55:567-574.
14. Hjalmarson A, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J Jr. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990;65:547-553.
15. Disegni E, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Zion M, Boyko V, Behar S. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. J Clin Epidemiol 1995;48:1197-1205.
16. Zuanetti G, Hernández-Bernal F, Rossi A, Comerio G, Paolucci G, Maggioni AP. Relevance of heart rate as a prognostic factor in myocardial infarction: The GISSI experience. Eur Heart 1999;1(Suppl H) :H52-H57.
17. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41, 021 patients. GUSTO-I Investigators. Circulation 1995;91:1659-1668.
18. Marchioli R, Avanzini F, Barzi F, et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart 2001;22:2085-2103.
19. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101:2557-2567.
20. Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: Prospective multinational observational study (GRACE). BMJ 2006;333:1079-1080.
21. Antoni ML, Boden H, Delgado V, Boersma E, Fox K, Schalij MJ, Bax JJ. Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J 2012;33:96-102.
22. Bangalore S, Messerli FH, Ou FS, et al. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: Results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J 2010;31:552-560.
23. Frank M, Aboyans V, Le Guyader A, Orsel I, Lacroix P, Cornu E, Laskar M. Usefulness of postoperative heart rate as an independent predictor of mortality after coronary bypass grafting. Am J Cardiol 2010;106:958-962.
24. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 1993;88:92-100.
25. Rambihar S, Gao P, Teo K, et al. Heart Rate is associated with Increased Risk of Major Cardiovascular Events, Cardiovascular and All-Cause Death in Patients with Stable Chronic Cardiovascular Disease-An Analysis of ONTARGET/TRANSCEND. Circulation 2010;122:A12667.
26. Gullestad L, Wikstrand J, Deedwania P, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 2005;45:252-259.
27. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103:1428-1433.
28. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008;101:865-869.
29. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-894.
30. Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Hansen JF. C-reactive protein, heart rate variability and prognosis in community subjects with no apparent heart disease. J Intern Med 2006;260:377-387.
31. Rogowski O, Shapira I, Shirom A, Melamed S, Toker S, Berliner S. Heart rate and microinflammation in men: A relevant atherothrombotic link. Heart 2007;93:940-944.
32. Kelly RP, Ting CT, Yang TM, Liu CP, Maughan WL, Chang MS, Kass DA. Effective arterial elastance as an index of arterial vascular load in humans. Circulation 1992;86:513-521.
33. Sa Cunha R, Pannier B, Benestos A, Siché JP, London GM, Mallion JM, Safar ME. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 1997;15:1423-1430.
34. Lang CC, Gupta S, Kalra P, Keavney B, Menown I, Morley C, Padmanabhan S. Elevated heart rate and cardiovascular outcomes in patients with coronary artery disease: Clinical evidence and pathophysiological mechanisms. Atherosclerosis 2010;212:1-8.
35. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001;104:1477-1482.
36. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-49F.
37. Daly CA, Clemens F, Sendon JL, et al. Inadequate control of heart rate in patients with stable angina: Results from the European heart survey. Postgrad Med J 2010;86:212-217.
38. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45, 852 patients with acute myocardial infarction: Randomised placebo-controlled trial [COMMIT]. Lancet 2005;366:1622-1632.
39. Thackray SD, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006;152:713. e9-13.
40. Poulter NR, Wedel H, Dahlöf B, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-913.
41. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008;26:351-356.
42. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 1990;66:779-785.
43. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 1988;319:385-392.
44. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: A meta-regression of randomized clinical trials. Eur Heart J 2007;28:3012-3019.
45. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-2536.
46. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-816.
47. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, ; BEAUTIFUL Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: A subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30:2337-2345.
48. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010;376:875-885.
49. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
50. Castagno D, Petrie MC, Claggett B, McMurray J. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 2012;33:1137-1141.
51. Cleland JGF, Cullington D. Digoxin. Quo Vadis? Circ Heart Fail 2009;2:81-85.
52. Mehara K, Iwai M, Adachi Y, Iwatsubo T, Usui T, Kamimura H. Hepatic uptake and excretion of (-)-N-{2-[(R)-3-(6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel if channel inhibitor, in rats and humans. Drug Metab Dispos 2008;36:1030-1038.
53. Elzein E, Zablocki J. A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 2008;17:1901-1910.